Literature DB >> 19279104

The LMP1 promoter can be transactivated directly by NF-kappaB.

Constantinos Demetriades1, George Mosialos.   

Abstract

A bioinformatic analysis identified two putative NF-kappaB binding sites in the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) promoter. The ability of p65RelA to interact with the LMP1 promoter was shown by in vitro and in vivo assays. Using an EBV-transformed lymphoblastoid cell line as a reporter system for the activity of the +40/-328 LMP1 promoter region, the functional importance of NF-kappaB and other transcription factor binding sites was demonstrated. p65RelA could also induce LMP1 expression from the EBV genome in Daudi and P3HR1 Burkitt's lymphoma cell lines. Finally, it was shown that p65RelA could cooperate with EBNA2 or the aryl hydrocarbon receptor in the transactivation of the LMP1 promoter. Our study established the importance of NF-kappaB and several cis-acting elements in the regulation of the LMP1 promoter in a latency III environment and highlighted a complex interplay between NF-kappaB and other transcription factors in this process.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19279104      PMCID: PMC2682074          DOI: 10.1128/JVI.00097-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter.

Authors:  Rongsheng Peng; Stephanie C Moses; Jie Tan; Elisabeth Kremmer; Paul D Ling
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit.

Authors:  Shunbin Ning; Leslie E Huye; Joseph S Pagano
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  Regulation of transactivation function of the aryl hydrocarbon receptor by the Epstein-Barr virus-encoded EBNA-3 protein.

Authors:  Elena V Kashuba; Katarina Gradin; Marja Isaguliants; Laszlo Szekely; Lorenz Poellinger; George Klein; Arunas Kazlauskas
Journal:  J Biol Chem       Date:  2005-10-28       Impact factor: 5.157

4.  Epigenetic determination of a cell-specific gene expression program by ATF-2 and the histone variant macroH2A.

Authors:  Marios Agelopoulos; Dimitris Thanos
Journal:  EMBO J       Date:  2006-10-12       Impact factor: 11.598

5.  Treatment of mice with 2,3,7,8-tetrachlorodibenzo-p-dioxin leads to aryl hydrocarbon receptor-dependent nuclear translocation of NF-kappaB and expression of Fas ligand in thymic stromal cells and consequent apoptosis in T cells.

Authors:  Iris A Camacho; Narendra Singh; Venkatesh L Hegde; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

6.  NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells.

Authors:  E D Cahir-McFarland; D M Davidson; S L Schauer; J Duong; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

7.  An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter.

Authors:  A Sjöblom; W Yang; L Palmqvist; A Jansson; L Rymo
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain.

Authors:  F Nitsche; A Bell; A Rickinson
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

9.  Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways.

Authors:  Gautier Goormachtigh; Tan-Sothéa Ouk; Alexandra Mougel; Denis Tranchand-Bunel; Eric Masy; Christophe Le Clorennec; Jean Feuillard; Georg W Bornkamm; Claude Auriault; Evelyne Manet; Véronique Fafeur; Eric Adriaenssens; Jean Coll
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

Review 10.  Ah receptor: dioxin-mediated toxic responses as hints to deregulated physiologic functions.

Authors:  Karl Walter Bock; Christoph Köhle
Journal:  Biochem Pharmacol       Date:  2006-03-20       Impact factor: 5.858

View more
  13 in total

1.  Nuclear factor κB represses the expression of latent membrane protein 1 in Epstein-Barr virus transformed cells.

Authors:  Mingxia Cao; Qianli Wang; Amy Lingel; Luwen Zhang
Journal:  World J Virol       Date:  2014-11-12

2.  Differentiation-Dependent LMP1 Expression Is Required for Efficient Lytic Epstein-Barr Virus Reactivation in Epithelial Cells.

Authors:  Dhananjay M Nawandar; Makoto Ohashi; Reza Djavadian; Elizabeth Barlow; Kathleen Makielski; Ahmed Ali; Denis Lee; Paul F Lambert; Eric Johannsen; Shannon C Kenney
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.

Authors:  Alexander M Price; Joshua E Messinger; Micah A Luftig
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

4.  Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor.

Authors:  Takayuki Murata; Chieko Noda; Yohei Narita; Takahiro Watanabe; Masahiro Yoshida; Keiji Ashio; Yoshitaka Sato; Fumi Goshima; Teru Kanda; Hironori Yoshiyama; Tatsuya Tsurumi; Hiroshi Kimura
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

Review 5.  Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation.

Authors:  Alexander M Price; Micah A Luftig
Journal:  Adv Virus Res       Date:  2014       Impact factor: 9.937

6.  Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation.

Authors:  Alexander M Price; Jason P Tourigny; Eleonora Forte; Raul E Salinas; Sandeep S Dave; Micah A Luftig
Journal:  J Virol       Date:  2012-08-01       Impact factor: 5.103

7.  Id1 interacts and stabilizes the Epstein-Barr virus latent membrane protein 1 (LMP1) in nasopharyngeal epithelial cells.

Authors:  Pok Man Hau; Chi Man Tsang; Yim Ling Yip; Michael S Y Huen; Sai Wah Tsao
Journal:  PLoS One       Date:  2011-06-20       Impact factor: 3.240

8.  Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.

Authors:  Andrea Bilger; Julie Plowshay; Shidong Ma; Dhananjay Nawandar; Elizabeth A Barlow; James C Romero-Masters; Jillian A Bristol; Zhe Li; Ming-Han Tsai; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  Oncotarget       Date:  2017-07-04

9.  Characterization of a Suppressive Cis-acting Element in the Epstein-Barr Virus LMP1 Promoter.

Authors:  Masahiro Yoshida; Takayuki Murata; Keiji Ashio; Yohei Narita; Takahiro Watanabe; H M Abdullah Al Masud; Yoshitaka Sato; Fumi Goshima; Hiroshi Kimura
Journal:  Front Microbiol       Date:  2017-11-22       Impact factor: 5.640

Review 10.  Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.

Authors:  Ramon Yarza; Mateo Bover; Maria Teresa Agulló-Ortuño; Lara Carmen Iglesias-Docampo
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.